[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate].
Recombinant Factor VIIa, a new therapeutic tool to treat severe bleeding caused by inhibitory haemophilia cases, some cases of thrombocytopenia and thrombocytopathy (e.g. severe type III von Willebrand disease) receives growing attention in clinical practice. Exogeneous FVIIa-in a supraphysiological concentration (clearly over 6 U/ml) seems to be able to generate quickly and safely (without thrombotic side effects) thrombin--the final enzyme of clotting--in physiological, or pathological conditions. A concise review about the possible mechanisms of action, indications, monitoring and clinical experience gained sofar with FVIIa is given in this report.
Udvardy
M
M
Debreceni Orvostudományi Egyetem, II. Belgyógyászati Klinika.
D005167:Factor VII / Q000008:administration & dosage*; D005168:Factor VII Deficiency / Q000628:therapy*; D006467:Hemophilia A / Q000628:therapy*; D006474:Hemorrhagic Disorders / Q000628:therapy*; D006801:Humans; D013921:Thrombocytopenia / Q000628:therapy*; D014842:von Willebrand Diseases / Q000097:blood* / Q000628:therapy
D005167:Factor VII
Uj lehetöség a faktorhiányos, az antitest okozta és a thrombocyta eredetü vérzékenység kezelésében: a rekombináns aktív VII-es faktor koncentrátum.